TY - JOUR
T1 - Uptake-Dependent and -Independent Effects of Fibroblasts-Derived Extracellular Vesicles on Bone Marrow Endothelial Cells from Patients with Multiple Myeloma
T2 - Therapeutic and Clinical Implications
AU - Lamanuzzi, Aurelia
AU - Saltarella, Ilaria
AU - Reale, Antonia
AU - Melaccio, Assunta
AU - Solimando, Antonio Giovanni
AU - Altamura, Concetta
AU - Tamma, Grazia
AU - Storlazzi, Clelia Tiziana
AU - Tolomeo, Doron
AU - Desantis, Vanessa
AU - Mariggiò, Maria Addolorata
AU - Desaphy, Jean François
AU - Spencer, Andrew
AU - Vacca, Angelo
AU - Apollonio, Benedetta
AU - Frassanito, Maria Antonia
N1 - Funding Information:
This research was funded by INNOLABS–POR Puglia grant number FESR-FSE 2014-2020 (Telemielolab) to A.V., by AIRC IG (grant number 25706) to C.T.S. and by Italian Ministry for Education, University and Research to J.-F.D. (grant PRIN number 20174TB8KW002 “Lioness”).
Publisher Copyright:
© 2023 by the authors.
PY - 2023/5
Y1 - 2023/5
N2 - Extracellular vesicles (EVs) have emerged as important players in cell-to-cell communication within the bone marrow (BM) of multiple myeloma (MM) patients, where they mediate several tumor-associated processes. Here, we investigate the contribution of fibroblasts-derived EVs (FBEVs) in supporting BM angiogenesis. We demonstrate that FBEVs’ cargo contains several angiogenic cytokines (i.e., VEGF, HGF, and ANG-1) that promote an early over-angiogenic effect independent from EVs uptake. Interestingly, co-culture of endothelial cells from MM patients (MMECs) with FBEVs for 1 or 6 h activates the VEGF/VEGFR2, HGF/HGFR, and ANG-1/Tie2 axis, as well as the mTORC2 and Wnt/β-catenin pathways, suggesting that the early over-angiogenic effect is a cytokine-mediated process. FBEVs internalization occurs after longer exposure of MMECs to FBEVs (24 h) and induces a late over-angiogenic effect by increasing MMECs migration, chemotaxis, metalloproteases release, and capillarogenesis. FBEVs uptake activates mTORC1, MAPK, SRC, and STAT pathways that promote the release of pro-angiogenic cytokines, further supporting the pro-angiogenic milieu. Overall, our results demonstrate that FBEVs foster MM angiogenesis through dual time-related uptake-independent and uptake-dependent mechanisms that activate different intracellular pathways and transcriptional programs, providing the rationale for designing novel anti-angiogenic strategies.
AB - Extracellular vesicles (EVs) have emerged as important players in cell-to-cell communication within the bone marrow (BM) of multiple myeloma (MM) patients, where they mediate several tumor-associated processes. Here, we investigate the contribution of fibroblasts-derived EVs (FBEVs) in supporting BM angiogenesis. We demonstrate that FBEVs’ cargo contains several angiogenic cytokines (i.e., VEGF, HGF, and ANG-1) that promote an early over-angiogenic effect independent from EVs uptake. Interestingly, co-culture of endothelial cells from MM patients (MMECs) with FBEVs for 1 or 6 h activates the VEGF/VEGFR2, HGF/HGFR, and ANG-1/Tie2 axis, as well as the mTORC2 and Wnt/β-catenin pathways, suggesting that the early over-angiogenic effect is a cytokine-mediated process. FBEVs internalization occurs after longer exposure of MMECs to FBEVs (24 h) and induces a late over-angiogenic effect by increasing MMECs migration, chemotaxis, metalloproteases release, and capillarogenesis. FBEVs uptake activates mTORC1, MAPK, SRC, and STAT pathways that promote the release of pro-angiogenic cytokines, further supporting the pro-angiogenic milieu. Overall, our results demonstrate that FBEVs foster MM angiogenesis through dual time-related uptake-independent and uptake-dependent mechanisms that activate different intracellular pathways and transcriptional programs, providing the rationale for designing novel anti-angiogenic strategies.
KW - angiogenesis
KW - angiogenic cytokines
KW - extracellular vesicles
KW - multiple myeloma
UR - http://www.scopus.com/inward/record.url?scp=85160803647&partnerID=8YFLogxK
U2 - 10.3390/biomedicines11051400
DO - 10.3390/biomedicines11051400
M3 - Article
C2 - 37239071
AN - SCOPUS:85160803647
SN - 2227-9059
VL - 11
JO - Biomedicines
JF - Biomedicines
IS - 5
M1 - 1400
ER -